Trulicity Alternatives & Comparison
How Trulicity (dulaglutide) compares to Ozempic, Mounjaro, Rybelsus — mechanism, trial weight-loss results, and cost — plus where to compare vetted providers.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Trulicity Alternatives Compared
Weekly GLP-1 that generally moves A1c and weight further at matched doses
Ozempic activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, and reduce blood sugar levels.
Both weekly GLP-1s for type 2 diabetes, and Ozempic is the stronger on both endpoints people ask about: −6.5 kg against Trulicity's −3.0 kg, and MACE −26% in SUSTAIN-6 against −12% in REWIND. One caveat worth stating, because it cuts the other way: REWIND enrolled a majority who had not yet had a cardiovascular event, which is a harder population in which to show benefit. Retail is close, near $990 either way, with savings cards limited to commercial insurance.
Full Ozempic vs Trulicity comparison →Works on GIP and GLP-1 together, typically the strongest glycemic and weight effect here
Mounjaro's tirzepatide activates both GIP and GLP-1 receptors — making it a "dual agonist" or "twincretin." For diabetes, this dual action powerfully lowers blood sugar by increasing insulin secretion and reducing glucagon.
Same manufacturer, successive generations. SURPASS-2 put Mounjaro 15 mg at −11.2 kg over 40 weeks against Trulicity 1.5 mg at −2.9 to −3.1 kg over 26 weeks. Trulicity has the completed cardiovascular result, REWIND's MACE −12%; Mounjaro's SURPASS-CVOT is pending 2027. Pricing is close — about $987 against $1,069 — with both savings cards restricted to commercial insurance. Trulicity's remaining case is the outcomes data and a step-therapy requirement that may put it first anyway.
Full Mounjaro vs Trulicity comparison →Daily oral GLP-1, if the weekly injection is what you want to avoid
Rybelsus delivers semaglutide — a GLP-1 receptor agonist — in tablet form by co-formulating each pill with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer that transiently raises gastric pH and helps the semaglutide peptide cross the gastric mucosa intact before stomach acid and proteases can degrade it.
Both are diabetes drugs, neither is approved for weight management, and the weight figures — −4.4 kg on Rybelsus at 26 weeks, −2 to −3 kg on Trulicity — come from diabetes programs rather than obesity trials. Rybelsus demands the fasting window that oral semaglutide absorption requires; Trulicity is one weekly injection with no food rules. Retail is near $1,029 and $987. For most people this decision is made by the formulary, not by these numbers.
Full Rybelsus vs Trulicity comparison →Compare compounded Semaglutide providers
Compounded semaglutide runs a median of $190/month across 481 vetted-provider price points (range $65–$1,585). Featured partners below, ranked by our partner-economics ordering.
Compare compounded Tirzepatide providers
Compounded tirzepatide runs a median of $258/month across 435 vetted-provider price points (range $83–$1,400). Featured partners below, ranked by our partner-economics ordering.
Compare every Trulicity provider
See current pricing, verification status, form, and states served across every vetted provider in one place.